Research analysts covering QHSLab.
Recent press releases and 8-K filings for USAQ.
QHSLab Reports Preliminary Unaudited 2025 Financial Results
USAQ
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- QHSLab, Inc. reported preliminary unaudited revenue of $2,676,074 for the year ended December 31, 2025, representing an increase of just over 25% compared to $2,131,926 in 2024.
- Gross profit margin expanded from approximately 64% in 2024 to approximately 67% in 2025, with gross profit growing over 32% to $1,795,182 in 2025.
- The company significantly reduced outstanding convertible debt and associated accrued interest from approximately $2.0 million to approximately $20,000 during Q4 2025, which is expected to reduce annual interest expense by more than $200,000.
- The Q-Cog pilot program began generating reimbursement activity in December 2025 and is anticipated to become a meaningful incremental revenue stream in 2026.
Jan 26, 2026, 1:00 PM
QHSLab Reports Strong 2025 Preliminary Unaudited Financial Results
USAQ
Earnings
Revenue Acceleration/Inflection
- QHSLab (USAQ) reported preliminary unaudited financial results for the year ended December 31, 2025, with revenue increasing 25% year over year to $2,676,074.
- Gross profit grew over 32% to $1,795,182 in 2025, and gross margins expanded from approximately 64% in 2024 to approximately 67% in 2025.
- The company substantially reduced outstanding convertible debt from approximately $2.0 million to approximately $20,000 in Q4 2025, which is expected to reduce annual interest expense by over $200,000.
- QHSLab's Q-Cog pilot program is beginning to generate reimbursement activity and is anticipated to become a meaningful incremental revenue stream in 2026.
Jan 26, 2026, 1:00 PM
QHSLab Initiates Board Expansion Process
USAQ
Board Change
Delisting/Listing Issues
- QHSLab Inc. (USAQ) has initiated a formal process to expand its board of directors by adding independent members.
- This initiative aims to strengthen governance, enhance oversight, and broaden strategic perspective, supporting future milestones including potential uplisting considerations.
- The move follows recent actions to simplify the capital structure, substantially eliminate legacy convertible debt, and complete a funding transaction.
- Troy Grogan, President, CEO, and Sole Director, stated that evolving the governance structure is a positive and necessary step for the company's next phase.
Jan 16, 2026, 1:00 PM
QHSLab issues unaudited financial and operational update
USAQ
Earnings
Debt Issuance
Revenue Acceleration/Inflection
- For the nine months ended September 30, 2025, QHSLab reported $1.99 million in revenue, a 32% increase year-over-year, and a net operating income before interest of $95,738.
- The company significantly reduced its outstanding convertible debt from approximately $1.4 million to $20,000 during the fourth quarter of 2025, anticipating an annual interest expense reduction of over $250,000.
- QHSLab ended December 31, 2025, with approximately $630,000 in cash and believes it exited the year in a cash-flow-positive operating position.
- As of January 6, 2026, the company has 13,418,899 shares of common stock outstanding, with approximately 2,429,525 shares in the public trading float.
Jan 6, 2026, 2:46 PM
QHSLab Provides Unaudited Financial and Operational Update
USAQ
Earnings
Guidance Update
Revenue Acceleration/Inflection
- QHSLab reported unaudited revenue of $1.99 million for the nine months ended September 30, 2025, representing a 32% year-over-year increase, with a gross profit of $1.32 million and net operating income before interest of $95,738.
- The company significantly reduced its outstanding convertible debt from approximately $1.4 million to $20,000, which is projected to reduce annual interest expense by more than $250,000.
- QHSLab ended 2025 with approximately $630,000 in cash and management anticipates reporting net income for the full year 2025, positioning the company for improved operating leverage in 2026.
- As of January 6, 2026, QHSLab has 13,418,899 shares of common stock outstanding, with approximately 2,429,525 shares constituting the public trading float.
Jan 6, 2026, 2:44 PM
QHSLab Completes Private Placement and Retires Convertible Debt
USAQ
New Projects/Investments
Revenue Acceleration/Inflection
- QHSLab Inc. completed a $500,000 private placement with accredited investors, providing new growth capital and strengthening its balance sheet.
- The company repurchased and retired more than $1.4 million of legacy convertible notes in November 2025, eliminating several million shares of potential dilution and over $200,000 in annualized interest expense.
- This capital injection and debt retirement improved QHSLab's liquidity and financial flexibility, enabling a shift in focus from balance-sheet repair to disciplined growth execution.
- For the first nine months of 2025, QHSLab reported revenue of $1.99 million, a 32 percent year-over-year increase, and a gross profit of $1.32 million, representing a 66 percent gross margin.
Dec 29, 2025, 1:30 PM
QHSLab Launches Q-Cog™ for Early Cognitive Impairment Detection
USAQ
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- QHSLab Inc. (OTCQB: USAQ) announced the launch of Q-Cog™, a comprehensive, cloud-based cognitive assessment designed for the early detection of Mild Cognitive Impairment (MCI) and dementia risks, on December 3, 2025.
- An initial pilot of Q-Cog™ with 168 patients aged 65 and older identified 54% (90 individuals) at high risk for cognitive impairment.
- The launch of Q-Cog™ is expected to expand QHSLab's reimbursable digital medicine platform, aligning with CMS screening guidelines and supporting risk adjustment and reimbursement under neurocognitive and behavioral health codes, thereby creating new scalable revenue opportunities.
Dec 3, 2025, 1:30 PM
QHSLab, Inc. Repurchases Legacy Debt and Reports Q3 2025 Financial Results
USAQ
Earnings
Debt Issuance
Revenue Acceleration/Inflection
- QHSLab, Inc. (USAQ) completed the repurchase and retirement of over $1.4 million in outstanding legacy convertible debt for a cash payment of $300,000 on November 18, 2025.
- This action eliminates future dilution risk by terminating conversion rights at $0.20 per share and removes more than $200,000 in annualized interest expense, strengthening the balance sheet.
- For Q3 2025, the company reported revenue of $737,066, a 35% increase year-over-year, and a gross profit of $493,631 with a 67% gross margin.
- Net income for Q3 2025 was $33,411, compared to a net loss of ($99,156) for the first nine months of 2025.
- As of November 20, 2025, QHSLab had 11,281,527 common shares outstanding.
Nov 18, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more